We previously identified FGF-21 as associated with colorectal cancer risk in a study investigating potential protein biomarkers of metabolic syndrome13, where we found it to be strongly associated with BMI and therefore of potential interest as a colorectal cancer screening biomarker. This evidence concerns the gene FGF21 and colorectal cancer.